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between groups with high vs. low biomarker levels,
showing that the biomarker panel predicted NRM [Hazard
Ratio¼11.4, p¼0.002 (adjusted)] (Fig 3).
We conclude that ST2, CXCL9, MMP3, and OPN represent
a biomarker panel for reliable, non-invasive diagnosis of
cGVHD as well as for correlation with cGVHD severity, and
prediction of NRM. Once further validated, these biomarkers
could help identify patients with cGVHD at risk for poor
outcomes with current treatment approaches.48
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Graft-versus-host disease (GVHD) remains the major
barrier to the success of allogeneic stem cell transplantationFigure 1. Anti-ST2 mAb treatment reduces GVHD severity and mortality by increas
allogeneic group. Mice were treated with anti-ST2 or lgG isotype control via intraper
GVHD score and (C) histopathologic analysis shows protection from GVHD in anti-ST2
modutates transcript expression in MLN T cells. *pc<0.05**p<0.01, ***p<0.001, IgG vs(SCT). We have reported that soluble suppression of tumori-
ginicity 2 (ST2) measured in plasma of post-SCT patients is a
marker for risk of therapy-resistant GVHD and death. ST2 is a
member of the IL-1 receptor family whose sole known ligand
is IL-33. Soluble ST2 acts as a decoy receptor for IL-33. Thus,
we hypothesized that blockade of soluble ST2 will increase
the amount of free IL-33 that will be able to bind to
membrane ST2 on CD4+ T cells, driving them toward a Th2
phenotype, which will alleviate GVHD. First, we found that
similar to plasma ST2 course in SCT patients, plasma ST2 was
markedly increased prior to and at the onset of GVHD
symptoms in multiple clinically relevant GVHD murine
models (B6 to C3H.SW shown, Fig. 1A). Based on this obser-
vation, anti-ST2 antibody given with a prophylactic schedule
(one dose before SCT and one dose at day+1 post-SCT)
signiﬁcantly reduced GVHD severity and mortality (Fig. 1B).
Pathology analysis indicated that anti-ST2 treated recipients
showed lower histopathologic score in liver and intestine
(Fig. 1C). Strikingly, anti-ST2 signiﬁcantly increased plasma
IL-33 (Fig. 1D). Whole transcriptome analysis of mesenteric
lymph node T cells showed that anti-ST2 modulated gene
expression of helper T cell (Th1/Th2) related cytokines (Fig.
1E), suggesting that ST2 blockade may affect the helper T
cell compartment. To further assess the effects of
ST2 blockade on helper T cells, we examined the Th1/Th2ing plasma IL-33 (A) The kinetics of plasma sST2 show increased sST2 levels in
itoneal injection on Day 1 and Day 1 post-transplantation (B) Survival, clinical
treated group. (D) Increased plasma IL-33 in anti-ST2 treated group. (E)Anti-ST2
Anti-ST2.
Figure 2. Blockade of ST2 shifts the Th1/Th2 balance toward Th2 phenotype and increases CD4D regulatory T cells. Spleen T cells were collected for intracellular
staining at day l0 post-transplantation. *p<0.05, **p<0.01.
Figure 3. Anti-ST2 mAb treatment preserves substantial GVL activity. (A) Survival cure. (B) GVHD score (bars) and percent of tumor relapse (lines). **p<0.01, IgG vs
Anti-ST2
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shifted Th1/Th2 balance toward a Th2 phenotype (Fig. 2).
In addition, ST2 blockade also induced expansion of
regulatory T cells (Tregs) (Fig. 2).
Given that anti-ST2 administration also up-regulated
expression of genes, such as Granzyme A, that can mediate
graft vs. leukemia (GVL) responses (Fig. 1E), we postulated
that ST2 blockade would not affect therapeutic GVL activity.
To conﬁrm this, we developed a clinically relevant model of
leukemia, in which C3H.SW recipients were challenged
with syngeneic GFP+ MLL-AF9 induced acute myeloid
leukemia cells. Our results indicated that administration of
anti-ST2 preserved substantial GVL activity and resulted in
signiﬁcantly improved leukemia-free survival (Fig. 3),
suggesting that anti-ST2 ameliorated GVHD and maintained
GVL response.
In summary, we found that prophylaxis with anti-ST2
antibody could alleviate GVHD severity and mortality whilepreserving GVL effect. ST2 blockade increased the level of
plasma IL-33, skewed the Th1/Th2 balance toward a Th2
phenotype, and induced Foxp3+Tregs (with preserved
expression of membrane ST2 [not shown]). Our ﬁndings
suggest that ST2 is a novel therapeutic target to ameliorate
GVHD.GRAFT PROCESSING
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Ex Vivo Expanded Multi-Speciﬁc Cytotoxic T Lymphocytes
Derived from HIV+ Patients and HIV Negative Donors
Using GMP Compliant Methodologies Recognize Multiple
HIV Antigens and Suppress HIV Replication
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